VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
India has taken the lead in recognising NAFLD as a major non-communicable disease
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for treatment of schizophrenia
Quinidine Sulphate helps manage rare irregular heartbeat conditions
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
Subscribe To Our Newsletter & Stay Updated
